BioNTech SE Sponsored ADR

BNTX Healthcare Biotechnology

BioNTech SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 9.07% from fiscal 2024.

Revenue
−16.4%
EPS
+708.4%
Free cash flow
−123.8%
Total debt
+44.4%

Quarter to September 2026, against a year earlier

87.01 1.15 +1.34%
Market cap
$21.6B
P/E
0.0×
Fwd P/E
−13.5×
Dividend yield
—
F-score
4/9
Altman Z
n/a
Beneish M
−2.74
Dividend safety
n/a

BioNTech SE Sponsored ADR (BNTX) P/E ratio

Alert me on P/E ratio

BioNTech SE Sponsored ADR has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 747× (February 2021) — the current reading is the lowest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 27.1× 653.24%
FY2022 3.6× (30.77%)
FY2021 5.2× (98.98%)
FY2020 510× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —

Quarterly newest first

Period P/E ratio Change
Sep 2026 0.0× —
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
24 more quarters

Against its own ten years

Low 0.0× High 747×
Ten-year median 0.0×
Current reading's percentile 51

P/E ratio against peers

Company P/E ratio
ROIV Roivant Sciences Ltd. compare n/m
BNTX BioNTech SE Sponsored ADR n/m
BBIO BridgeBio Pharma, Inc. compare n/m
INSM Insmed, Inc. compare n/m
ALNY Alnylam Pharmaceuticals, Inc. compare 7.9×
ASND Ascendis Pharma A/S compare 18.3×
EXEL Exelixis, Inc. compare 19.9×
GMAB Genmab A/S Sponsored ADR compare 41.7×
INCY Incyte Corporation compare 56.3×
Biotechnology industry median 10.3×
Healthcare sector median 25.2×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on BNTX